Joanna Kovalski
Assistant Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Positions (1)
Joanna Kovalski
University of North Carolina at Chapel Hill
5 months ago
Postdoctoral Position Available at the Kovalski Lab, University of North Carolina at Chapel Hill The Kovalski Lab at the Lineberger Comprehensive Cancer Center is recruiting a postdoctoral fellow to join a newly launched research group focused on the intersection of RNA biology and cancer biology . The lab studies how cancer hijacks RNA biology processes to drive tumor progression, with a particular emphasis on how RNA-binding proteins are functionally repurposed during oncogenic transformation to rewire the cancer cell proteome. The research program combines cutting-edge approaches including RNA structure probing , proximity proteomics , CLIP-seq , ribosome profiling , and in vivo cancer models . This is a strong opportunity for candidates interested in post-transcriptional regulation, RNA-protein interactions, and mechanistic cancer research. UNC-Chapel Hill and the Lineberger Comprehensive Cancer Center provide a collaborative and resource-rich environment for postdoctoral training, with access to world-class core facilities and a vibrant cancer research community. Applicants should be highly motivated and interested in RNA biology, cancer biology, or both. The post does not specify a deadline, stipend, or formal application portal; interested candidates are encouraged to contact the lab and visit the lab website for more information.
5 months ago
Articles (4)
Year:
2025
Year:
2025
Selective inhibition of mRNA translation is a promising strategy for modulating the activity of disease-associated genes, yet achieving both high potency and specificity remains challenging. Rocaglamide A (RocA), a molecular glue, inhibits translation by clamping eIF4A onto polypurine motifs found in many transcripts, thereby limiting RocA’s specificity. Here, we developed RocASO, a chemical conjugate that links RocA to an antisense oligonucleotide (ASO) capable of base-pairing with defined mRNA sequences, thus directing RocA’s clamping mechanism to chosen targets and enhancing overall potency and specificity. We show that RocASOs are compatible with various types of ASO modalities, including gapmers that induce the degradation of target RNAs. RocASOs were designed to effectively knock down endogenous genes ( PTGES3 , HSPA1B ) and SARS-CoV-2 viral RNA, the latter conferring potent antiviral activity in cells. These findings establish RocASO as a versatile platform for programmable translational inhibition with therapeutic potential.
Year:
2025
Oncogenic protein dosage is tightly regulated to enable cancer cells to adapt and survive. Whether this is regulated at the level of translational control and the key factors in cis and trans remain unknown. The Myc oncogene is a central paradigm of an exquisitely regulated oncogene and a major driver of pancreatic ductal adenocarcinoma (PDAC). Using a functional genome-wide CRISPRi screen in PDAC cells, we identified activators of selective MYC translation through its 5’ untranslated region (5’UTR) and validated four RNA binding proteins (RBPs), including epitranscriptome modifiers. Among these RBPs, our top hit was RBM42, which is highly expressed in PDAC and predicts poor survival. Combining polysome sequencing and CLIP-seq analyses, we find that RBM42 binds and selectively regulates the translation of MYC and a precise, yet vital suite of pro-oncogenic transcripts, including JUN and EGFR . Mechanistically, employing IP-mass spectrometry analysis, we find that RMB42 is a novel ribosome-associated protein (RAP). Using DMS-Seq and mutagenesis analysis, we show that RBM42 directly binds and remodels the MYC 5’UTR RNA structure, facilitating the formation of the translation pre-initiation complex. Importantly, RBM42 is necessary for human PDAC cell growth and fitness and PDAC tumorigenesis in xenograft mouse models in a Myc-dependent manner in vivo . In PDAC patient samples, RBM42 expression is correlated with Myc protein levels and transcriptional activity. This work transforms our understanding of the translational code in cancer and offers a new therapeutic opening to target the expression of oncogenes.
Year:
2024
Collaborators (8)
Davide Ruggero
Professor
University of California
Nevan Krogan
Professor
University of California, San Francisco
Rushika M. Perera
Assistant Professor
University of California
Danielle Swaney
University of California, San Francisco
Duygu Kuzuoglu Ozturk
Assistant Prof
Sabancı University
Melanie Ott
Professor
University of California, San Francisco
Hani Goodarzi
Associate Professor
University of California, San Francisco
Kevan Shokat
Professor
UCSF Medical Center
Make your next move.
Prepare your application
Review drafts before you send them.